Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center conducted a survey to compare the attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
They randomly surveyed 120 hematologists and 120 solid tumor oncologists at the institution; 182 clinicians (76%) responded.
The survey questions examined the participants’ attitudes toward various aspects of end-of-life care, including use of palliative systemic therapy.
The researchers found significant differences in attitudes and beliefs toward end-of-life care. Hematologic specialty and comfort level with prescribing treatment to patients with Eastern Cooperative Oncology Group performance status 4 and an expected survival of 1 month were associated with the decision to treat in the last month of life.
Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|